Harrisson S et al. Six month interim results of MSDC-0602K in a large phase 2b NASH study demonstrate significant improvement in liver enzymes and glycemic control (NCT02784444). (Abstract PS-111)
DNA-pas belooft minder bijwerkingen, betere patiëntenzorg en lagere kosten
apr 2023